Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.
J Acquir Immune Defic Syndr
; 67(4): 365-9, 2014 Dec 01.
Article
em En
| MEDLINE
| ID: mdl-25202923
ABSTRACT
Concerns that the injectable contraceptive depot-medroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácidos Fosforosos
/
Adenina
/
Infecções por HIV
/
Acetato de Medroxiprogesterona
/
Anticoncepcionais Femininos
/
Fármacos Anti-HIV
/
Desoxicitidina
/
Profilaxia Pré-Exposição
Limite:
Animals
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article